Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
91-105 of 235
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiersThe Future of MS Management: Novel Agents and Clinical Approaches
Marisa McGinley, DO
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
NeuroFrontiersReevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Modern MS Care: Navigating Treatment Options for Better Patient Outcomes
NeuroFrontiersModern MS Care: Navigating Treatment Options for Better Patient Outcomes
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
NeuroFrontiersRecognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
NeuroFrontiersPregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the MAPLE-MS Pharmacovigilance Program
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
NeuroFrontiersEpigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
David Gate, PhD
- advertisement
Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
NeuroFrontiersAdvancing MS Care: Evolving Treatments and High-Efficacy Approaches
Marisa McGinley, DO
Understanding MS: Managing Hidden and Overlooked Symptoms
NeuroFrontiersUnderstanding MS: Managing Hidden and Overlooked Symptoms
Marisa McGinley, DO
Recognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
NeuroFrontiersRecognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
Marisa McGinley, DO
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
NeuroFrontiersASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
NeuroFrontiersNew-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
NeuroFrontiersSafety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
- advertisement
Early Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
NeuroFrontiersEarly Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
NeuroFrontiersMetabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
Restoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
NeuroFrontiersRestoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
